Your browser is no longer supported. Please, upgrade your browser.
Settings
GBSN Great Basin Scientific, Inc. daily Stock Chart
GBSN [NASD]
Great Basin Scientific, Inc.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand878.27M Perf Week-38.46%
Market Cap0.70M Forward P/E- EPS next Y- Insider Trans- Shs Float0.51M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float0.18% Perf Quarter-
Sales2.81M P/S0.25 EPS this Y- Inst Trans- Short Ratio0.00 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price1575840.00 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range- - - Perf YTD-54.29%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High- Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low- ATR0.00
Employees134 Current Ratio- Sales Q/Q34.80% Oper. Margin- RSI (14)- Volatility28.58% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.38 Prev Close0.00
ShortableYes LT Debt/Eq- EarningsMar 07 AMC Payout- Avg Volume111.73M Price0.00
Recom3.00 SMA20-45.10% SMA50-45.10% SMA200-45.10% Volume154,206,702 Change-20.00%
Feb-24-17 05:17PM  GREAT BASIN SCIENTIFIC, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Material Modification to Rig -9.09%
Feb-17-17 06:06AM  GREAT BASIN SCIENTIFIC, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Material Modification -18.75%
Feb-16-17 05:15PM  GREAT BASIN SCIENTIFIC, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to +14.29%
Feb-15-17 07:30AM  Great Basin Scientifics Staph ID/R Blood Culture Panel Clinical Evaluation and Rapid Identification Analysis Published in Journal of Clinical Microbiology GlobeNewswire
Feb-14-17 08:45AM  Great Basin Scientific Announces Filing of Registration Statement on Form S-1 GlobeNewswire -12.50%
08:39AM  GREAT BASIN SCIENTIFIC, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
Feb-10-17 09:17AM  GREAT BASIN SCIENTIFIC, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Regulation FD Dis +5.88%
09:00AM  Great Basin Scientific Announces Corporate Restructuring and Reduction in Principal of 2016 Convertible Note GlobeNewswire
Feb-03-17 05:12PM  GREAT BASIN SCIENTIFIC, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Material Modification to Rig
07:00AM  Great Basin Scientifics Shiga Toxin Direct Test Clinical Evaluation and Cost Analysis Published in Journal of Clinical Microbiology GlobeNewswire
Feb-02-17 08:18AM  GREAT BASIN SCIENTIFIC, INC. Files SEC form 8-K, Other Events
Feb-01-17 07:00AM  Great Basin Scientific Completes Clinical Trial, Submits FDA 510(k) Application for Bordetella Direct Test GlobeNewswire
Jan-31-17 01:04PM  GREAT BASIN SCIENTIFIC, INC. Financials
08:59AM  GREAT BASIN SCIENTIFIC, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to
Jan-26-17 07:30AM  Great Basin Scientific Stock Symbol Reverts to GBSN GlobeNewswire
06:06AM  GREAT BASIN SCIENTIFIC, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Material Modification to Rig
Jan-24-17 09:26AM  Great Basin Scientific Announces Preliminary Fourth Quarter 2016 Revenue GlobeNewswire
Jan-20-17 08:30AM  Great Basin Announces Request to Withdraw S-1 Registration Statement and Amendment to $75 Million 2016 Convertible Note GlobeNewswire
Dec-28-16 11:17AM  Great Basin Scientific Stock Symbol Temporarily Changed to GBSND GlobeNewswire
07:30AM  Great Basin Announces Effectiveness of Reverse Stock Split of Common Stock and Authorized Share Increase GlobeNewswire
Dec-22-16 06:45PM  Great Basin Scientific Shareholders Approve Reverse Stock Split and Authorized Share Increase During Special Meeting GlobeNewswire
Great Basin Scientific, Inc., a molecular diagnostic testing company, develops and commercializes molecular diagnostic systems that are designed to test hospital-acquired infections. The company's platform provides C. diff test, a rapid medical diagnostic test for the detection of C. diff, a gram-positive bacteria that causes severe diarrhea and other intestinal disorders. It also provides Group B streptococcus test, which is used to detect Group B streptococcus from an anal/vaginal swab of a pregnant woman. The company's assays in clinical trials include Staphylococcus identification and resistance blood infection panel that is designed to identify species of staphylococcus infections, detect the mecA gene that confers drug resistance directly from positive blood cultures, and provide information on the antibiotic resistance profile of the bacteria; and Shiga toxin producing Escherichia coli (E. coli) test that identifies shiga toxin produced by E. coli. Its assays under development include Staphyloccocus aureus (SA) pre-surgical nasal screen, a rapid test for the presence of SA in the nasal passages of a pre-surgical patient; Stool bacterial pathogenic panel, which is designed to detect the causes of food poisoning; Candida blood infections panel that is designed to identify the five species of Candida directly from positive blood cultures; Pertussis test for contagious respiratory disease caused by the bacterium Bordetella pertussis; and CT/NG test for chlamydia tracomatis/neisseria gonorrhoeae. The company sells its diagnostic tests through a direct sales force in the United States, as well as through distributors in the European Union and New Zealand. The company was formerly known as Diagnostic Micro Arrays, Inc. and changed its name to Great Basin Scientific, Inc. in April 2006. Great Basin Scientific, Inc. is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Citadel GP LLC10% OwnerOct 06Buy0.3019,5155,855755,701Oct 11 09:09 PM
Citadel GP LLC10% OwnerOct 06Sale0.3020,8156,245734,886Oct 11 09:09 PM